Skip to content
lifestyle.longislandreport.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
InnoCare Pharma
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
July 5, 2026
2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients
June 15, 2026
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
June 5, 2026
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
June 2, 2026
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
May 28, 2026
InnoCare Announces Approval of Orelabrutinib in Australia
May 27, 2026
2026 ASCO | Pivotal Data of InnoCare’s Novel BCL2 Inhibitor Mesutoclax Released
May 22, 2026
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
April 28, 2026
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
April 23, 2026
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
April 21, 2026
1
2
Next Page
→